Science AI Journal
Medicine · Research topic

Open research questions in Diabetes Treatment and Management

1,290 gap statements mined from Diabetes Treatment and Management papers in our 7.9M-paper local library, which holds 5,875 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Diabetes Treatment and Management? See the ranked Medicine journals.

What the literature leaves open

  • The study is a pilot study with a small sample size. The in vitro assays failed to demonstrate a direct pharmacological effect of GLP-1 RA in modulating OCN surface expression on monocytes. The study identifies the need for further research to understand the effect of GLP-1 RA on OCN-expressing monocytes.

    Modulation of circulating osteocalcin-expressing monocytes by glucagon like peptide-1 receptor agonists in type 2 diabetes: an exploratory pilot study · 2026 · DOI

  • There is a need for further preclinical research on the cardiac effects of GLP-1 receptor co-agonists. Preclinical studies in mice may be misleading when studying cardiac effects in humans. There are controversies in the literature regarding the use of GLP-1 receptor co-agonists to treat cardiac diseases.

    Future GLP-1 receptor co-agonists and their cardiac effects · 2026 · DOI

  • The need to quantify therapy- and patient-level associations with switching. The lack of studies examining the temporal dynamics of switching among GLP-1 receptor agonists.

    Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland · 2026 · DOI

  • There is a need to investigate the effect of dapagliflozin on left atrial volume index in type 2 diabetes mellitus patients without established cardiovascular disease. The study aims to provide preliminary echocardiographic observations on the possible association between dapagliflozin and early structural changes in diabetic cardiomyopathy.

    Dapagliflozin is associated with a reduction in left atrial volume index in type 2 diabetes mellitus without established cardiovascular disease · 2026 · DOI

  • The analysis highlights the need to address disparities in healthcare outcomes among migrant populations with T2D. The study notes the importance of considering ethnic-and migration-related differences in the quality of diabetes care.

    Quality of care for migrant populations with type 2 diabetes mellitus in Italy: a retrospective analysis of data from the the Italian AMD (Associations of Medical Diabetologists) annals initiative · 2026 · DOI

  • There is a lack of data on the onset and management of erythrocytosis in a routine clinical setting, particularly in type 2 diabetes patients.

    Sodium–glucose cotransporter 2 inhibitor-associated erythrocytosis in type 2 diabetes: a retrospective cohort study · 2026 · DOI

  • There is a gap in early cardio-renal risk prevention in type 2 diabetes. Current guidelines may appear conservative or unclear for patients with early markers of risk. There is a need for a broader, risk-based treatment model.

    Bridging the gap in early cardio-renal risk prevention in type 2 diabetes: evidence, guidelines, and real-world insights from the PRECARE NO LiMITS initiative · 2026 · DOI

  • There is a lack of age-stratified evidence for GLP1 receptor agonists and SGLT2 inhibitors, particularly in older patient populations. Older patients, especially those 75 years or older, are underrepresented in nearly all trials. There is inconsistent reporting of age-stratified data in clinical trials and European public assessment reports.

    Availability of age-stratified evidence for GLP1 receptor agonists and SGLT2 inhibitors: an analysis of European public assessment reports with a focus on older patients · 2026 · DOI

  • There is a need to understand the mechanisms of GLP-1-based therapies in cardiovascular disease. There is a need to evaluate the long-term safety and optimal use of GLP-1-based therapies in clinical practice.

    GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications · 2026 · DOI

  • One of the challenges is the potential for high-altitude hypoxia to alter drug pharmacokinetics, potentially affecting treatment outcomes. Another challenge is the need to simulate different high-altitude scenarios using acute and chronic exposure protocols. The study also faced the challenge of quantifying renal SGLT2 expression using ELISA.

    Time-dependent pharmacokinetic changes and renal SGLT2 expression alterations of dapagliflozin under high-altitude hypoxia in diabetic rats · 2026 · DOI

  • Investigate the long-term effects of GLP-1 RA therapy on CD14+OCN+ monocytes. Examine the mechanisms by which GLP-1 RAs modulate CD14+OCN+ monocytes.

    Modulation of circulating osteocalcin-expressing monocytes by glucagon like peptide-1 receptor agonists in type 2 diabetes: an exploratory pilot study · 2026 · DOI

  • The study notes that the files lacked patient-level encounter, diagnosis, and treatment dates. The study acknowledges the potential for selection bias due to restriction to active patients.

    Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study · 2026 · DOI

  • The GLP-1RA group was small and non-randomized. Residual confounding (cumulative LDL-C exposure, anti-platelet or RAAS therapy, blood-pressure control, residual inflammatory risk) may bias trajectories. Multiplicity across plaque subcomponents inflates type-I error in a limited cohort.

    GLP-1 receptor agonists after ACS in diabetes: credible plaque signals, but comparators, confounding, and access will decide impact · 2026 · DOI

  • The paper identifies methodological and statistical inconsistencies in the meta-analysis by Jamal et al. The inconsistencies include unit-of-analysis error and incorrect use of standard deviation.

    Methodological and statistical inconsistencies compromise the efficacy and safety analyses of orforglipron · 2026 · DOI

  • The files lacked patient-level encounter, diagnosis, and treatment dates, - the analysis describes an active-export-defined clinical cohort rather than a prospectively recruited or population-based sample, - the supplied files did not preserve the underlying ICD-code algorithms or a separate clinician-adjudication field, - no multiplicity adjustment was applied, - possible intermediates or common effects may…

    Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study · 2026 · DOI

  • Complementing traditional MACE endpoints with outcomes that better reflect systemic vulnerability, including all-cause mortality, recurrent-event frameworks, and multistate models integrating heart failure, renal decline, and death - Precision-oriented designs enriching for populations in whom metabolic stress and cardiorenal disease drive…

    Beyond superiority: preserved cardiovascular efficacy and emerging signals in SURPASS-CVOT · 2026 · DOI

  • The paper identifies a gap in the design of cardiovascular outcome trials, particularly in the choice of endpoints and the alignment with drug mechanism. The study highlights the challenges of demonstrating superiority in cardiovascular outcomes research.

    Beyond superiority: preserved cardiovascular efficacy and emerging signals in SURPASS-CVOT · 2026 · DOI

  • Further studies are needed to understand the pathogenesis of SGLT-2 inhibitor-associated polycythemia, - Research on the long-term clinical implications of SGLT-2 inhibitor-associated polycythemia is required, - Investigations into the effects of SGLT-2 inhibitors on tissue oxygenation and cardiac and renal injury…

    Polycythemia due to SGLT-2 inhibitors: who is at risk? · 2026 · DOI

  • The study was not powered for secondary endpoints, - No formal correction for multiple comparisons was applied, - The study lacks a control group, - The sample size is relatively small…

    Dapagliflozin is associated with a reduction in left atrial volume index in type 2 diabetes mellitus without established cardiovascular disease · 2026 · DOI

  • Longitudinal studies are needed to evaluate long-term cardiovascular and microvascular outcomes among migrant populations with T2D and to determine whether observed differences in risk factor control translate into disparities in clinical endpoints - interventional studies should assess the effectiveness of culturally tailored strategies such as multilingual educational materials, dietitian-led interventions…

    Quality of care for migrant populations with type 2 diabetes mellitus in Italy: a retrospective analysis of data from the the Italian AMD (Associations of Medical Diabetologists) annals initiative · 2026 · DOI

  • The study involved only Italian experts, - The study was based on a modified Delphi method, - The study had a limited number of participants…

    A Modified Delphi consensus on early management of combined cardiovascular risk factors in adult patients with type 2 diabetes in Italy · 2026 · DOI

  • Investigate the relative weight of pre-existing predisposing conditions and pharmacodynamic effects of SGLT2i, - Explore the class-specific pharmacological mechanism…

    Sodium–glucose cotransporter 2 inhibitor-associated erythrocytosis in type 2 diabetes: a retrospective cohort study · 2026 · DOI

  • Gastrointestinal adverse effects still remain a concern, - Limited data available for individuals older than 80 years, - Clinical decision-making must balance potential benefit with the risks associated with adverse effects…

    GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications · 2026 · DOI

  • Investigate the effects of high-altitude hypoxia on dapagliflozin pharmacokinetics in humans - Examine the long-term effects of high-altitude hypoxia on renal SGLT2 expression and glycemic response - Study the potential interactions between dapagliflozin and other medications under high-altitude…

    Time-dependent pharmacokinetic changes and renal SGLT2 expression alterations of dapagliflozin under high-altitude hypoxia in diabetic rats · 2026 · DOI

  • The study is a cross-sectional observational study, - The sample size is limited to 231 patients, - The study only considers patients from a tertiary-level hospital…

    The Prescription Pattern, Care‐Seeking Behavior and Glycemic Status Among the Diabetic Patients in a Tertiary‐Level Hospital of Bangladesh: A Cross‐Sectional Observational Study · 2026 · DOI

Most-cited papers in Diabetes Treatment and Management

Most recent work

Find a gap in your own Diabetes Treatment and Management sub-topic

This page shows what the Diabetes Treatment and Management literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,200 open questions
Dementia and Cognitive Impairment Research
2,789 open questions
Substance Abuse Treatment and Outcomes
2,285 open questions
Cancer Immunotherapy and Biomarkers
2,273 open questions
Liver Disease Diagnosis and Treatment
2,102 open questions
Sports Performance and Training
1,952 open questions
Parkinson's Disease Mechanisms and Treatments
1,915 open questions
Mosquito-borne diseases and control
1,849 open questions
Open questions raised by papers listed on this page include: (1) There is a need for further preclinical research on the cardiac effects of GLP-1 receptor co-agonists (“Future GLP-1 receptor co-agonists and their cardiac effects”, 2026); (2) The lack of studies examining the temporal dynamics of switching among GLP-1 receptor agonists (“Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest…”, 2026); (3) There is a need to investigate the effect of dapagliflozin on left atrial volume index in type 2 diabetes mellitus patients without established cardiovascular disease (“Dapagliflozin is associated with a reduction in left atrial volume index in…”, 2026); (4) There is a lack of data on the onset and management of erythrocytosis in a routine clinical setting, particularly in type 2 diabetes patients (“Sodium–glucose cotransporter 2 inhibitor-associated erythrocytosis in type 2…”, 2026); (5) There is a lack of age-stratified evidence for GLP1 receptor agonists and SGLT2 inhibitors, particularly in older patient populations (“Availability of age-stratified evidence for GLP1 receptor agonists and SGLT2…”, 2026). 1,290 gap statements have been mined from Diabetes Treatment and Management papers in our 7.9M-paper local library, which holds 5,875 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.